dr. axel grothey on differences between correct and concur studies in mcrc
Published 9 years ago • 316 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:47
dr. axel grothey on the time course of regorafenib-associated adverse events
-
1:28
surivival benefit of regorafenib in correct and concur trials
-
1:35
dr. axel grothey on bevacizumab beyond progression in metastatic colorectal cancer
-
2:03
dr. axel grothey on the side effect profile of regorafenib in metastatic colorectal cancer
-
0:57
dr. axel grothey examines the use of adjuvant oxaliplatin in colon cancer
-
1:34:24
colorectal cancer risk, screening and prevention
-
5:23
what you need to know about colorectal cancer
-
8:01
types of colon cancer w/ dr. julian sanchez, colorectal surgeon
-
1:55
dr. grothey describes the phase iii correct study
-
2:04
dr. grothey on left- versus right-sided tumors in crc
-
11:50
colon cancer management - dr. axel grothey, part 1
-
1:18
dr. grothey on treatment landscape of mcrc
-
0:58
dr. kim reviews studies investigating regorafenib in mcrc
-
1:43
axel grothey, md | what is signatera?
-
6:17
colorectal cancer & ctdna updates with dr. axel grothey
-
1:48
dr. grothey discusses novel agents for colorectal cancer
-
8:35
colorectal cancer and the correct trial - interview with axel grothey, md, at asco 2012
-
1:53
the role of sidedness in colorectal cancer
-
0:47
axel grothey, md, on patient selection & treatment algorithms in 2nd and 3rd line crc
-
27:23
key insights in colorectal cancer
-
11:50
colon cancer management - dr. axel grothey, part 2
-
8:38
a review of select trials in colorectal cancer